| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5202333 | HELSINN HLTHCARE | Tricyclic 5-HT3 receptor antagonists |
Apr, 2015
(9 years ago) | |
| US6297375 | HELSINN HLTHCARE | 4-phenyl-pyridine derivatives |
Mar, 2023
(1 year, 1 month ago) | |
| US10233154 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10676440 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US10961195 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| US9951016 | HELSINN HLTHCARE | Crystalline forms of an NK-1 antagonist |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US9943515 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US8951969 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US8623826 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| US9271975 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Sep, 2031
(7 years from now) | |
Akynzeo is owned by Helsinn Hlthcare.
Akynzeo contains Netupitant; Palonosetron Hydrochloride.
Akynzeo has a total of 13 drug patents out of which 2 drug patents have expired.
Expired drug patents of Akynzeo are:
- US5202333
- US6297375
Akynzeo was authorised for market use on 10 October, 2014.
Akynzeo is available in capsule;oral dosage forms.
Akynzeo can be used as method of treating emesis, prevention of chemotherapy-induced nausea and vomiting, use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Drug patent challenges can be filed against Akynzeo from 10 October, 2018.
The generics of Akynzeo are possible to be released after 25 September, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
NCE-1 date: 10 October, 2018
Market Authorisation Date: 10 October, 2014
Treatment: Method of treating emesis; Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy...
Dosage: CAPSULE;ORAL
AKYNZEO family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908907 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| US9403772 | HELSINN HLTHCARE | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| US8426450 | HELSINN HLTHCARE | Substituted 4-phenyl pyridines having anti-emetic effect |
May, 2032
(8 years from now) | |
| US11312698 | HELSINN HLTHCARE | Fosnetupitant chloride hydrochloride having improved stability |
May, 2032
(8 years from now) | |
| US10717721 | HELSINN HLTHCARE | Substituted piperaziniums for the treatment of emesis |
May, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186357 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(6 years from now) | |
| US10828297 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Dec, 2030
(6 years from now) | |
| US8895586 | HELSINN HLTHCARE | Methods of treating emesis |
May, 2032
(8 years from now) | |
| US10208073 | HELSINN HLTHCARE | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
May, 2032
(8 years from now) | |
| US11529362 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(13 years from now) | |
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(13 years from now) | |
Akynzeo is owned by Helsinn Hlthcare.
Akynzeo contains Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride.
Akynzeo has a total of 11 drug patents out of which 0 drug patents have expired.
Akynzeo was authorised for market use on 19 April, 2018.
Akynzeo is available in solution;intravenous, powder;intravenous dosage forms.
Akynzeo can be used as use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Drug patent challenges can be filed against Akynzeo from 19 April, 2022.
The generics of Akynzeo are possible to be released after 02 June, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 19, 2023 |
NCE-1 date: 19 April, 2022
Market Authorisation Date: 19 April, 2018
Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
AKYNZEO family patents